Skip to main content

Table 3 Baseline patient characteristics for different dosages of LMWH

From: Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital

Variable Major underdose (n = 223) Mild underdose (n = 51) Recommended dose (n = 34) Excess dose (n = 4) PValue
Age, y 62.1 ± 10.7 67.0 ± 11.3 68.6 ± 12.8 77.0 ± 17.5 <0.001
 ≥75 years, n (%) 24 (10.8) 19 (37.3) 19 (55.9) 3 (75) <0.001
Female, n (%) 60 (26.9) 10 (19.6) 6 (17.6) 1 (25) 0.531
Weight (kg) 70.3 ± 9.2 58.2 ± 9.1 55.8 ± 8.8 71.5 ± 9.1 <0.001
BMI 24.7 ± 2.9 21.6 ± 2.6 21.0 ± 3.1 26.2 ± 3.1 <0.001
Diagnosis, n (%)      0.167
 STEMI 37 (16.6) 9 (17.6) 6 (17.6) 1 (25)  
 UA/NSTEMI 126 (56.5) 34 (66.7) 21 (61.8) 2 (50)  
 Atrial fibrillation 54 (24.2) 6 (11.8) 7 (20.6) 0  
 DVT 6 (2.7) 2 (3.9) 0 1 (25)  
Hypertension 134 (60.1) 34 (66.7) 23 (67.6) 3 (75) 0.668
Diabetes mellitus 53 (23.8) 7 (13.7) 9 (26.5) 0 0.267
Severe RI 0 0 3 (8.8) 4 (100) <0.001
Creatinine, mg/dl 0.8 ± 0.2 0.8 ± 0.2 1.0 ± 0.3 2.5 ± 1.0 <0.001
Creatinine clearance, ml/min 90.6 ± 26.8 69.7 ± 16.4 61.3 ±22.6 24.9 ± 5.0 <0.001
Administration duration, d 4.1 ± 2.1 3.9 ± 1.8 4.0 ± 1.6 6.5 ± 5.6 0.128
Length of hospital stay, d 8.8 ± 5.7 9.4 ± 5.8 8.2 ± 4.6 14.8 ± 16.8 0.179
Major adverse vascular events, n (%) 6 (2.7) 1 (2.0) 1 (2.9) 2 (50) <0.001
  1. Abbreviations: LMWH, Low molecular weight heparin; BMI, body mass index; STEMI, ST-segment elevation myocardial infarction; UA/NSTEMI, Unstable angina/Non ST-segment elevation myocardial infarction; DVT, Deep vein thrombosis; RI, renal insufficient.